Molecular Hematopathology

Cell and Tissue Based Molecular Pathology

Volumn , Issue , 2009, Pages 305-324

  Cook, James R ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957748205     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044306901-7.50030-4     Document Type: Chapter

References (70)

1. Faderl S, Hochhaus A, Hughes T Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin North Am 2004, 18:657-670.
2. Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for "harmonizing" current methodology for detecting BCR/ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108(1):28-37.
3. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
4. Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR/ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
5. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR/ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 1995, 85:2632-2638.
6. Radich JP, Gooley T, Bryant E, et al. The significance of BCR/ABL molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood 2001, 98:1701-1707.
7. Tefferi A, Dewald GW, Litzow ML, et al. Chronic myeloid leukemia: Current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc 2005, 80:390-402.
8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
9. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRα and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
10. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005, 434:1144-1148.
11. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168.
12. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
13. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
14. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-Kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12:312-314.
15. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995, 92:10560-10564.
16. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1/PDGFRα in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006, 30(8):965-970.
17. Tefferi A, Elliott MA, Pardanani A Atypical myeloproliferative disorders: Diagnosis and management. Mayo Clin Proc 2006, 81:553-563.
18. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001, 25:603-625.
19. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005, 106:3618-3620.
20. Dash A, Gilliland DG Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14:49-64.
21. Ferrara F, Del Vecchio L Acute myeloid leukemia with t(8;21)/ AML1/ETO: A distinct biological and clinical entity. Haematologica 2002, 87:306-319.
22. Frohling S, Scholl C, Gilliland DG, et al. Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 2005, 23:6285-6295.
23. Gilliland DG, Griffin JD The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
24. Jaffe E, Harris N, Stein H, Vardiman JW Tumours of Haematopoietic and Lymphoid Tissues 2001, IARC Press, Lyon.
25. Nishino HT, Chang CC Myelodysplastic syndromes: Clinicopathologic features, pathobiology, and molecular pathogenesis. Arch Pathol Lab Med 2005, 129:1299-1310.
26. Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/ MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003, 102:2395-2402.
27. Steensma DP, List AF Genetic testing in the myelodysplastic syndromes: Molecular insights into hematologic diversity. Mayo Clin Proc 2005, 80:681-698.
28. Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 2005, 19:1345-1349.
29. Armstrong SA, Look AT Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2006, 23:6306-6314.
30. Douet-Guilbert N, Morel F, Le Bris MJ, et al. Cytogenetic studies in T-cell acute lymphoblastic leukemia (1981-2002). Leuk Lymphoma 2004, 45:287-290.
31. Harrison CJ The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Rev 2001, 15:49-59.
32. Silverman LB, Sallan SE Newly diagnosed childhood acute lymphoblastic leukemia: Update on prognostic factors and treatment. Curr Opin Hematol 2003, 10:290-296.
33. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
34. Bagg A Molecular diagnosis in lymphoma. Curr Hematol Rep 2005, 4:313-323.
35. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003, 101:1149-1154.
36. Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: Reassessing the reported association with t(9;14). Hum Pathol 2004, 35:447-454.
37. Cook JR Paraffin section interphase fluorescence in situ hybridization in the diagnosis and classification of non-Hodgkin lymphomas. Diagn Mol Pathol 2004, 13:197-206.
38. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt lymphoma. N Engl J Med 2006, 354:2431-2442.
39. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: Correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287-295.
40. Farinha P, Gascoyne RD Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005, 23:6370-6378.
41. Guo Y, Karube K, Kawano R, et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with BCL2 amplification, BCL6 translocation or other gene aberrances. Leukemia 2005, 19:1058-1063.
42. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/ c-Myc translocation generally have a poor prognosis. Mod Pathol 2006, 19:25-33.
43. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
44. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002, 100:1177-1184.
45. Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002, 99:3806-3812.
46. Remstein ED, Kurtin PJ, Buno I, et al. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000, 110:856-862.
47. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871-3879.
48. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
49. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004, 18:1722-1726.
50. Wotherspoon AC, Dogan A, Du MQ Mucosa-associated lymphoid tissue lymphoma. Curr Opin Hematol 2002, 9:50-55.
51. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2003, 100:9991-9996.
52. Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005, 106:296-303.
53. Bergsagel PL, Kuehl WM Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
54. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004, 64:1546-1558.
55. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32): Evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
56. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
57. Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005, 24:2461-2473.
58. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100:1579-1583.
59. Stewart AK, Fonseca R Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005, 23:6339-6344.
60. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 2006, 25:1560-1570.
61. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003, 102:4261-4269.
62. Kadin ME, Carpenter C Systemic and primary cutaneous anaplastic large-cell lymphomas. Semin Hematol 2003, 40:244-256.
63. Pekarsky Y, Zanesi N, Aqeilan R, et al. Tcl1 as a model for lymphomagenesis. Hematol Oncol Clin North Am 2004, 18:863-879. ix.
64. Ravandi F, Kantarjian H, Jones D, et al. Mature T-cell leukemias. Cancer 2005, 104:1808-1818.
65. Renedo M, Martinez-Delgado B, Arranz E, et al. Chromosomal changes pattern and gene amplification in T-cell non-Hodgkin's lymphomas. Leukemia 2001, 15:1627-1632.
66. Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood 2006, 107:1255-1264.
67. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK-negative systemic anaplastic large-cell lymphoma: Differential diagnostic and prognostic aspects-a review. J Pathol 2003, 200:4-15.
68. Wlodarska I, Martin-Garcia N, Achten R, et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002, 33:243-251.
69. Worth A, Thrasher AJ, Gaspar HB Autoimmune lymphoproliferative syndrome: Molecular basis of disease and clinical phenotype. Br J Haematol 2006, 133:124-140.
70. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004, 164:1837-1848.